KLK3 and prostate carcinoma: In respect to prostate cancer, of the subset of variables included in the final model, those showing statistical significance were PSA level > 20 ng/mL with reduced mean cost to USD 2735.29 (95% CI 60.37–9377.99) when compared to PSA level not stated, and distant metastases (determined) also with reduced mean costs to USD 2758.35 (95% CI 28.62–9938.10) when compared to distant metastases (undetermined) (Table 4).